AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kenhott who wrote (161)	11/29/2005 9:44:28 PM
From: tuck	Read Replies (1) of 332

Subset analysis . . . finance.messages.yahoo.com So it appears that while the study will end near the end of the 1st quarter of next year, the first results won't be out till the second half. I might ride the covered write a bit longer than January. RE: pipe; that's about all they've got except for a couple of preclinical programs. With the convertible debt looming, a failure by 1067 basically means good to zero, or at least low single digits, definitely less than cash -- which is about $5 bucks a share. One of the most binary events to come along in a while. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next